Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH.

Aliment Pharmacol Ther · 2025 · PMC11908112 · PMID 39984821

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The percentage of participants with > 30% reduction in LFC was 22%–36% in the pegbelfermin groups compared with 6% for placebo at Week 24 (between‐group significance not reported), and 20%–23.1% in the pegbelfermin groups compared to 8.8% for placebo at Week 48 (between‐group differences from placebo did not reach statistical significance).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.